Mr Peter Kazanoff > Simpson Thacher & Bartlett LLP > New York, United States > Lawyer Profile

Simpson Thacher & Bartlett LLP
NEW YORK, NY 10017-3954
United States
Peter Kazanoff photo

Work Department



Partner focusing on M&A, securities, and derivative litigations. M&A representations include private equity transactions involving KKR and other leading sponsors, as well as strategic transactions involving TD Ameritrade, Change Healthcare, People’s United, First Data, GGP, Microsoft, Tyco, CorpBanca, Eaton, Xerox, and Mars. Securities and derivative representations include Fairfield Greenwich in Madoff-related matters, TD Bank in Stanford-related matters, Envision, Dollar General, KKR Biomet, Ubiquiti Networks, PAAMCO Prisma Holdings and leading underwriters in offering-related litigations.


Joined the Firm in 1997; Partner since 2006. Editor of Securities Law Alert.


The University of Chicago Law School (J.D., cum laude, 1997); Bowdoin College (A.B., magna cum laude, 1992).

Lawyer Rankings

United States > Dispute resolution > M&A litigation: defense

(Hall of Fame)

Peter KazanoffSimpson Thacher & Bartlett LLP

Simpson Thacher & Bartlett LLP in New York has long been a market leader in M&A litigation and continues to be involved in cutting-edge matters, with a prime example is its work for technology company MultiPlan Corporation in the most prominent SPAC-related case in the market. The matter, in which MultiPlan was dismissed from the case, concerns allegations of breach of fiduciary duty in the merger with special purpose acquisition company Churchill III and claims that the merger was inherently conflicted. The case, led by practice co-head Jonathan Youngwood and up-and-coming partner Stephen Blake, is a milestone in reshaping the law to accommodate the unique qualities of SPACs. Paul Curnin retired in 2021, with seasoned trial lawyer Lynn Neuner taking up his role has global co-chair of litigation, alongside Youngwood. The firm has a deep bench of talented litigators, among them Peter Kazanoff, who is acting for Envision Healthcare Corporation in shareholder litigations concerning its $9.9bn sale to KKR; Palo Alto-based James Kreissman, who frequently acts for global technology companies; and Craig Waldman, who is also heavily involved in the Envision case.